最近有sellside在call sandoz, thesis是后面的gold decade of LOE -> biosimilar market to continue double-digit growth, potential risk: fda & ema towards regulatory streamlining...想起了之前的$梯瓦制药(TEVA)$ ，也仿制药大厂，然后转型...值得回头学习一波